[Pharmacology of beta-receptor blockers].
In the last few years beta-receptor blockers have been introduced in the therapy of congestive heart failure. beta-receptor blockers probably can reduce mortality of congestive heart failure. The mechanism underlying the therapeutic efficacy of beta-receptor blockers is most likely due to a reduction of increased endogenous noradrenaline plasma concentrations and their negative effects on physiological and biochemical processes in the myocardial cell. beta-receptor blockers can be divided into several classes. Some of them have additional properties different from beta-receptor blockers. The possible therapeutic value of these additional properties will be discussed.
Schmitz
W
W
Institut für Pharmakologie und Toxikologie, Westfälischen Wilhelms-Universität, Münster.
D000067956:Adenylyl Cyclase Inhibitors; D000319:Adrenergic beta-Antagonists / Q000145:classification / Q000494:pharmacology*; D000818:Animals; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D009206:Myocardium / Q000378:metabolism; D009638:Norepinephrine / Q000097:blood; D013318:Stroke Volume / Q000187:drug effects / Q000502:physiology; D013329:Structure-Activity Relationship; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology
D000067956:Adenylyl Cyclase Inhibitors; D000319:Adrenergic beta-Antagonists; D009638:Norepinephrine
Pharmakologie von beta-Rezeptorenblockern.